Saturday, 31 October 2026European Markets

ACCOR And EXOR NV Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - accor (ac.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
accor (ac.pa) €33.86 2.2% 7.64%
exor nv (exo.as) €81.94 0.56% 17.9%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. accor (ac.pa)

2.2% forward dividend yield and 7.64% return on equity

accor sa operates a chain of hotels worldwide. it operates through three segments: management & franchise; services to owners and hotel assets; and others. the company owns, operates, manages, and franchises hotels. it also provides digital services to independent hotel operators through d-edge platform; gekko solutions for leisure and travel industry and large companies; and concierge and customized services through john paul, as well as hotel booking services; and other services in events, fine dining, and entertainment through paris society and potel & chabot platforms. in addition, the company offers distribution activities, such as private sales of hotel accommodation and luxury vacations through verychic platform; rental of private residences operated by onefinestay; and coworking spaces through wojo and mama works. further, it provides hotel management, procurement, cash management, it, and advertising services, as well as various advisory services. accor sa was founded in 1967 and is headquartered in issy-les-moulineaux, france.

earnings per share

as for profitability, accor has a trailing twelve months eps of €1.21.

pe ratio

accor has a trailing twelve months price to earnings ratio of 27.98. meaning, the purchaser of the share is investing €27.98 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.64%.

yearly top and bottom value

accor's stock is valued at €33.86 at 17:30 est, higher than its 52-week high of €32.97.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, accor's stock is considered to be oversold (<=20).

volatility

accor's last week, last month's, and last quarter's current intraday variation average was 2.40%, 0.69%, and 1.21%.

accor's highest amplitude of average volatility was 2.40% (last week), 1.12% (last month), and 1.21% (last quarter).

volume

today's last reported volume for accor is 93548 which is 87.01% below its average volume of 720599.

more news about accor.

2. exor nv (exo.as)

0.56% forward dividend yield and 17.9% return on equity

exor n.v., together with its subsidiaries, engages in the luxury goods, automotive, agricultural and construction equipment, commercial vehicles, and professional football businesses worldwide. the company designs, engineers, produces, and sells luxury performance sports cars under the ferrari brand. it also offers automotive vehicles and mobility solutions under the abarth, alfa romeo, chrysler, citroen, dodge, ds, fiat, fiat professional, jeep, lancia, maserati, mopar, opel, peugeot, ram, and vauxhall brands; and retail and dealer financing, and rental services for the automotive sector, as well as sells service parts. in addition, the company designs, produces, markets, sells, and finances agricultural and construction equipment, trucks, commercial vehicles, buses, engines, and car spare parts. further, it manages professional football teams under the juventus football club name; publishes the economist, il secolo xix, la repubblica and la stampa, and other newspapers and magazines; offers digital and advertising, and conference and electronic services; and operates three national radio stations, including radio deejay. additionally, the company provides furniture, homeware, apparel, leather goods, jewelry, and accessories; and offers footwear. the company was founded in 1899 and is headquartered in amsterdam, the netherlands. exor n.v. is a subsidiary of giovanni agnelli b.v.

earnings per share

as for profitability, exor nv has a trailing twelve months eps of €12.23.

pe ratio

exor nv has a trailing twelve months price to earnings ratio of 6.7. meaning, the purchaser of the share is investing €6.7 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.9%.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on jun 2, 2023, the estimated forward annual dividend rate is 0.44 and the estimated forward annual dividend yield is 0.56%.

moving average

exor nv's value is above its 50-day moving average of €78.02 and way above its 200-day moving average of €73.62.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, exor nv's stock is considered to be oversold (<=20).

more news about exor nv.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,514 source documents archived
Query this data → isubstrate.com